Rizatriptan and sumatriptan are not the same medication, but they belong to the same drug class and work in a very similar way. Both are triptans, a family of drugs designed specifically to treat migraine attacks. They target the same receptors in the brain, produce similar effects, and share most of the same precautions. The differences come down to speed, potency at standard doses, available forms, and how they interact with other medications.
How Both Drugs Work
Triptans activate serotonin receptors (specifically the 5-HT1B and 5-HT1D subtypes) in the brainstem and the blood vessels surrounding the brain. This does two things: it narrows dilated blood vessels in the head, and it blocks the release of inflammatory compounds from nerve endings around those vessels. That combination interrupts the chain of events that produces migraine pain, nausea, and sensitivity to light or sound. Because rizatriptan and sumatriptan bind to the same receptors and trigger the same downstream effects, switching from one to the other feels broadly similar for most people.
Efficacy at Standard Doses
Head-to-head trials have consistently given rizatriptan a slight edge in pain relief. In a large comparison published in the journal Neurology, 40% of patients taking rizatriptan 10 mg were completely pain-free at two hours, compared with 33% of patients taking sumatriptan 100 mg. That seven-percentage-point gap is statistically significant, though both drugs helped the majority of patients reach at least mild pain levels within the same window.
Sustained relief over 24 hours also favors rizatriptan. In a comparative study of both drugs in acute migraine, about 63% of rizatriptan patients remained pain-free through the full 24-hour period, versus roughly 47% of sumatriptan patients. Migraine recurrence, where the headache fades and then returns within the same day, is one of the most frustrating aspects of triptan treatment, so this difference matters in real-world use.
Speed of Relief
Rizatriptan begins working within about 30 minutes for some patients when taken as a 10 mg tablet. At that 30-minute mark, roughly 20% of people in clinical trials had already reached a meaningful reduction in pain. Sumatriptan tablets generally take 30 to 60 minutes to produce noticeable relief at the standard oral dose. The gap narrows when sumatriptan is given as a nasal spray or injection, both of which absorb faster than a swallowed tablet.
Dosing Differences
The two drugs use different dose ranges because they have different potencies by weight. Rizatriptan comes in 5 mg and 10 mg tablets, with a maximum of 30 mg in 24 hours. Sumatriptan oral tablets start at 25 mg and go up to 100 mg per dose, with a 24-hour ceiling of 200 mg. If a first dose doesn’t fully resolve the migraine, both drugs allow a second dose after at least two hours, but you should not exceed the daily limit for either one.
Rizatriptan is also available as an orally disintegrating tablet that dissolves on the tongue without water, which can be helpful when nausea makes swallowing a pill difficult.
Available Forms
This is one of the biggest practical differences between the two. Rizatriptan comes only in oral forms: a standard tablet and a dissolving wafer. Sumatriptan is available in a much wider range of delivery methods, including oral tablets, nasal spray, nasal powder, and a self-administered injection. The injectable form works the fastest of any triptan option and is often reserved for people whose migraines come on very rapidly or who vomit early in an attack. If you need something other than a pill, sumatriptan gives you more choices.
A Key Drug Interaction
One important distinction involves propranolol, a beta-blocker commonly prescribed for migraine prevention. Propranolol significantly increases rizatriptan levels in the blood, so anyone taking propranolol must cut the rizatriptan dose in half, using only 5 mg per dose with a maximum of 15 mg per day. For children under 40 kg who take propranolol, the combination is contraindicated entirely. Sumatriptan does not have this interaction with propranolol, making it the simpler choice if you already take a beta-blocker for prevention.
Both drugs share the same class-wide precautions. Neither should be taken within 24 hours of the other or within 24 hours of any other triptan. Both carry warnings about use in people with uncontrolled high blood pressure, coronary artery disease, or a history of stroke. And both can contribute to serotonin syndrome if combined with certain antidepressants, particularly SSRIs or SNRIs, though the actual risk in practice is low.
Side Effects
The side effect profiles overlap heavily because the mechanism is the same. The most common complaints with both drugs include dizziness, drowsiness, fatigue, and what are sometimes called “triptan sensations,” a feeling of tightness, pressure, or tingling in the chest, neck, or throat. These sensations are not dangerous in most cases, but they can be alarming if you’re not expecting them. Nausea can also occur, though it’s often hard to separate from the migraine itself.
Neither drug has a clearly worse side effect profile than the other at standard doses. Individual tolerance varies, and it’s common for someone to find one triptan more agreeable than another for reasons that don’t show up in group averages.
How to Choose Between Them
If you need the fastest possible oral relief and don’t take propranolol, rizatriptan’s slightly quicker onset and higher two-hour pain-free rate make it a reasonable first choice. If you take propranolol for migraine prevention, sumatriptan avoids the dose-adjustment issue entirely. If you need a non-oral option because of severe nausea or rapid-onset attacks, sumatriptan’s nasal and injectable forms fill a gap that rizatriptan simply can’t. Cost and insurance coverage also play a role: both are available as generics, but your plan may favor one over the other.
Many people with migraine try more than one triptan before settling on the one that works best for them. The drugs are similar enough that switching is straightforward, and a poor response to one does not predict failure with the other. Roughly 30% of people who don’t respond well to one triptan will respond to a different one.